

1 **Characterisation of placental, fetal brain and maternal cardiac structure and function in**
2 **pre-eclampsia using MRI**

3 **Short title: Maternal-fetal changes in pre-eclampsia**

4 Megan Hall MRCOG, BSc (Hons)^{1,2}, Antonio de Marvao MRCP, PhD^{1,3,4}, Ronny Schweitzer
5 MD^{3,4}, Daniel Cromb MRCPCH, BSc (Hons)², Kathleen Colford, BSc (Hons), PGDip², Priya
6 Jandu, MSc⁵, Declan P O'Regan, FRCP, FRCR, PhD⁴, Alison Ho, MRCOG, PhD^{1,2}, Anthony
7 Price, PhD^{2,6}, Lucy C. Chappell, FRCOG, PhD, FMedSci¹, Mary A. Rutherford, MRCPCH, FRCR,
8 MD², Lisa Story MRCOG, PhD^{1,2}, Pablo Lamata, PhD⁶, Jana Hutter, PhD^{2,6}

9 1. Department of Women and Children's Health, King's College London, UK

10 2. Centre for the Developing Brain, King's College London, UK

11 3. School of Cardiovascular Medicine, King's College London, UK

12 4. MRC London Institute of Medical Sciences, Imperial College London, UK

13 5. GKT School of Medical Education, King's College London, UK

14 6. Centre for Medical Engineering, King's College London, UK

15

16 Corresponding author: Megan Hall

17 First Floor, South Wing

18 St Thomas' Hospital

19 London

20 SE1 7UH

21 megan.hall@kcl.ac.uk

22 +447906542307

23

24 Total word count: 3754

25 **Abstract**

26 *Background*

27 Pre-eclampsia is a multiorgan disease of pregnancy that has short- and long-term
28 implications for the woman and fetus, whose immediate impact is poorly understood. We
29 present a novel multi-system approach to MRI investigation of pre-eclampsia, with
30 acquisition of maternal cardiac, placental, and fetal brain anatomical and functional
31 imaging.

32 *Methods*

33 A prospective study was carried out recruiting pregnant women with pre-eclampsia, chronic
34 hypertension, or no medical complications, and a non-pregnant female cohort. All women
35 underwent a cardiac MRI, and pregnant women underwent a fetal-placental MRI. Cardiac
36 analysis for structural, morphological and flow data was undertaken; placenta and fetal
37 brain volumetric and T2* data were obtained. All results were corrected for gestational age.

38 *Results*

39 Seventy-eight MRIs were obtained during pregnancy. Pregnancies affected by pre-eclampsia
40 demonstrated lower placental and fetal brain T2*. Within the pre-eclampsia group, three
41 placental T2* results were within the normal range, these were the only cases with normal
42 placental histopathology. Similarly, three fetal brain T2* results were within the normal
43 range; these cases had no evidence of cerebral redistribution on fetal Dopplers. Cardiac MRI
44 analysis demonstrated higher left ventricular mass in pre-eclampsia with 3D modelling
45 revealing additional specific characteristics of eccentricity and outflow track remodelling.

46 *Conclusions*

47 We present the first holistic assessment of the immediate implications of pre-eclampsia on
48 the placenta, maternal heart, and fetal brain. As well as having potential clinical implications
49 for the risk-stratification and management of women with pre-eclampsia, this gives an
50 insight into disease mechanism.

51

52 What is new?

- 53 • We propose a comprehensive MRI protocol for maternal cardiac and fetal-placental
54 imaging that is safe in pregnancy and acceptable to women, and report on the
55 largest set of functional placental MRI data in pre-eclamptic pregnancies
- 56 • The findings suggest altered oxygenation and microstructure in the placenta, which
57 is associated with similar changes in the fetal brain
- 58 • The study identifies a specific pattern of remodelling in the maternal left ventricle
59 that is associated with pre-eclampsia

60

61 What are the clinical implications?

- 62 • We demonstrate that MRI provides maternal and fetal insights into pre-eclamptic
63 pregnancies that cannot be obtained by other means during pregnancy
- 64 • Functional placental MRI may be able to differentiate between preeclampsia disease
65 severities, while fetal brain imaging may help refine neurodevelopmental prognostic
66 assessment of children exposed to pre-eclampsia in utero
- 67 • A specific 3D pattern of left ventricular remodelling and thickening was found to be
68 discriminant of the presence of pre-eclampsia and may provide a basis for improved
69 clinical risk stratification

70

71 **Non-standard abbreviations and acronyms**

72 ADC = apparent diffusion coefficient

73 bpm = beats per minute

74 CO = cardiac output

75 EDV = end diastolic volume

76 ESV = end systolic volume

77 FGR = fetal growth restriction

78 FOV = field of view

79 GCS = global circumferential strain

80 GLS = global longitudinal strain

81 GRS = global radial strain

82 IQR = interquartile range

83 LV = left ventricular

84 LVM = left ventricular mass

85 TE = echo time

86 TR = repetition time

87 **Introduction**

88 Pre-eclampsia occurs when placental malperfusion, and a resultant release of soluble
89 factors into the circulation, causes maternal vascular endothelial injury with subsequent
90 hypertension and multi-organ damage.¹ The Incidence is between 2 and 8%, with
91 geographical variation.² Globally, 14% of maternal deaths are associated with hypertensive
92 diseases of pregnancy,³ which can occur secondary to multiple complications including renal
93 and hepatic failure, stroke, eclampsia, pulmonary oedema, and disseminated intravascular
94 coagulopathy. Cardiac manifestations include reduced cardiac output,⁴ increased vascular
95 resistance, left ventricular hypertrophy,⁵ and diastolic dysfunction.⁶ After the postnatal
96 period, women who have had pre-eclampsia remain at an increased risk of vascular disease
97 and ischaemic heart disease.^{7,8} While it is well recognised that maternal biochemical
98 abnormalities can be detected prior to clinical onset of pre-eclampsia, there is also some
99 evidence that cardiovascular maladaptation precedes the diagnosis of pre-eclampsia:
100 echocardiography has demonstrated abnormalities in left ventricular mass in the late third
101 trimester prior to the development of term pre-eclampsia.^{9,10}

102 Cardiac magnetic resonance imaging (MRI) combines excellent spatial and temporal
103 resolution, and is the gold-standard non-invasive method of assessing cardiac morphology
104 and function. In contrast with echocardiography, cardiac MRI is not limited by geometric
105 assumptions in assessing ventricular volumes and image acquisition is less operator-
106 dependent. This allows highly reproducible and accurate assessment of cardiac structure
107 and function,¹¹ making it the ideal modality for assessing differences between small
108 groups.¹² We have provided pilot data demonstrating feasibility of cardiac MRI in pregnancy,
109 but large prospective studies are still required.¹³

110 For the fetus, pre-eclampsia is associated with fetal growth restriction (FGR) and
111 complications such as placental abruption; excluding congenital anomalies, 5% of stillbirths
112 occur in women with pre-eclampsia (Cantwell et al, 2011). In infants born to women with
113 pre-eclampsia, increased rates of hypertension and cardiac dysfunction, stroke, cognitive
114 dysfunction and psychiatric morbidity have been demonstrated.¹⁴

115 Postnatally obtained placental histopathological correlates with pre-eclampsia include both
116 villous and vascular lesions,¹⁵ but sufficient *in vivo* and *in vitro* modelling of placental
117 development in disease is lacking. MRI offers an opportunity for *in vivo* study of the
118 placenta in pre-eclampsia, as well as evaluation of maternal and fetal structures. Recent
119 studies applying functional MRI techniques to the placenta have proposed reduced
120 oxygenation in the pre-eclamptic placenta via demonstration of increased heterogeneity
121 and decreased mean T2*.^{16,17} There is evidence of decreased placental diffusivity in small
122 for gestational age fetuses.^{18,19} Furthermore, advances in acquisition and reconstruction
123 techniques have allowed more detailed investigation of the fetal brain.

124 Here we describe a multi-system approach to MRI investigation of pre-eclampsia, with
125 acquisition of maternal cardiac, placental, and fetal brain anatomical and functional
126 imaging.

127 **Methods**

128 A prospective observational study was performed between 2019 and 2022 at Guy's and St
129 Thomas' NHS Foundation Trust (London Dulwich Ethics Committee 08/LO/1958). Additional
130 high-risk placental and fetal datasets were obtained from a previous study (London Dulwich
131 Ethics Committee 16/LO/1573). Additional non-pregnant control datasets were obtained
132 from a previous study (London - West London & GTAC Research Ethics Committee
133 17/LO/0034).

134 Women were recruited into four categories: non-pregnant controls, pregnant controls,
135 women with pre-eclampsia, and pregnant women with chronic hypertension; a fifth
136 category 'complicated pregnancies' was created retrospectively for women who had been
137 recruited as controls but had developed other pregnancy complications and this group was
138 excluded from further analysis. Women with diabetes and a hypertensive disorder were
139 analysed within the appropriate hypertensive cohort. For all groups inclusion criteria
140 included a body mass index (BMI) $<40\text{kg/m}^2$ (with the MRI bore size the limiting factor),
141 aged 16-50 years, and no contraindication to MRI such as non-compatible metal implants or
142 claustrophobia. All women could undergo up to three scans.

143 Inclusion criteria for the control group was women with no previous cardiovascular or
144 inflammatory cardiac history. Pregnant controls were excluded if they had a multi-fetal
145 pregnancy or fetal congenital anomalies. Pregnant controls were moved into the
146 complicated pregnancy cohort if they developed any other complications of pregnancy, had
147 an infant born preterm, below the 3rd centile, above the 97th centile, or that required
148 neonatal intensive care for any reason. Additionally, age and ethnicity matched non-
149 pregnant controls, having undergone equivalent imaging, were recruited from the UK Digital

150 Heart Project (UKDHP) at Imperial College London. Enrolment into this study excluded
151 participants who had known cardiovascular or metabolic disease, as previously described.²⁰

152 Case inclusion criteria was a diagnosis of pre-eclampsia (including superimposed on chronic
153 hypertension) defined by the International Society for the Study of Hypertension in
154 Pregnancy as hypertension with one of the following new-onset conditions at 20 weeks'
155 gestation or beyond: proteinuria, acute kidney injury, hepatic dysfunction, neurological
156 features, haemolysis or thrombocytopenia, or fetal growth restriction (Brown et al, 2018).
157 Women with chronic hypertension were recruited as a separate cohort.

158 Demographic and clinical information, including on previous obstetric history, was collected
159 on all participants. Neonatal outcomes including gestation at birth, mode of delivery,
160 condition at birth, need for neonatal support, and birthweight were collected.

161 *MRI*

162 After informed consent was obtained, participants had an MRI on a clinical 1.5T Philips
163 Ingenia scanner using a combined 24-channel posterior and torso (dStream) coil. Maternal
164 comfort in the supine position was achieved by careful positioning of the head and legs on
165 elevated cushions, back padding, and additional cushions as requested. The MRI was
166 performed in two sessions (maternal cardiac, and fetal-placental) each of which lasted
167 around 30 minutes. A break was given in the middle of the session. In order to reduce any
168 bias that could arise from maternal anxiety at the start of the scan, women with an odd case
169 study ID underwent fetal-placental imaging first, and those with an even ID underwent
170 cardiac imaging first.

171 An obstetrician or midwife was present for all scans. Maternal temperature was recorded
172 before and after the scan. Continuous oxygen saturations were measured, and blood
173 pressure was taken every 10 minutes.

174 The protocol is illustrated in Figure 1.

175 *Fetal-placental MRI*

176 Fetal brain and whole uterus structural imaging was performed in five planes (transverse
177 centred on fetal brain; two opposing sagittal oblique planes; maternal coronal plane and
178 maternal sagittal plane) in order to obtain whole uterus and dedicated placental images.
179 MRI was undertaken using 2D-single-shot Turbo Spin Echo (resolution 1.5x1.5x2.5mm, field
180 of view (FOV) 320x320x110mm, echo time (TE) 180ms). Fetal body imaging was performed
181 for clinical reporting only.

182 Placental T2* mapping was obtained using a multi-echo gradient-echo sequence (2.5mm
183 isotropic, FOV=300x300x110mm, TE=11, 58, 117, 176ms). Placental diffusion-weighted
184 imaging used a single-shot echo-planar-imaging sequence with parameters adapted to meet
185 the expected diffusivity (1 b=0, 6 b=375, 6 b=750; transverse relaxation (TR)=6.6ms,
186 TE=78ms, matrix = 512x512x56, resolution 2x2x4mm). Both sequences were repeated twice
187 to improve data robustness.

188 *Cardiac MRI*

189 Anatomical and functional cardiac MRI sequences were acquired using commonly employed
190 sequences adapted to reduce acoustic noise and heating, and so improve suitability in
191 pregnancy. Views taken included: 4 chamber, 2 chamber, 3 chamber, short axis and outflow
192 (acquired using dynamic balanced steady state free precession sequences with 30 cardiac
193 phases, 11 second breath-hold, FA=60, TE/TR~2/4ms, resolution=1.7x1.7x8mm); and a short

194 axis stack (14 slices, sense=2, resolution 2x2x10mm). Phase contrast flow sequences of the
195 ascending and descending aorta, and the superior vena cava were acquired with individually
196 adapted encoding velocities (30 phases, 14 second breath-holds, sense=2,
197 resolution=2.5x2.5x8mm). A pragmatic decision was made to obtain inferior vena cava
198 images during the 'fetal-placental' portion of the MRI as the coil was appropriately placed.
199 The scanning parameters are summarised in Table 1. Images acquired are demonstrated in
200 Figure 2.

201 Non-pregnant controls from the healthy control group underwent an equivalent cardiac MRI
202 protocol on a 1.5-T Philips Achieva system (Best, the Netherlands) as previously described.²⁰

203 *Analysis*

204 The placenta was visually inspected on a T2 image. Manual outlining was performed on a
205 functional scan mapped to subsequent scans. Monoexponential fitting was performed to
206 obtain T2* maps. Mean placenta T2*, histogram skewness and kurtosis, and mean
207 diffusivity (as the apparent diffusion coefficient – ADC) were calculated.

208 Brain volume (supratentorial tissues excluding brainstem and cerebrospinal fluid) was
209 manually segmented on functional maps. Mean T2* values were obtained by averaging the
210 T2* maps from manually outlined brains.

211 The cardiac MRIs were analysed using cvi42 post-processing software (Version 5.1.4, Circle
212 Cardiovascular Imaging Inc., Calgary, Canada), using standard clinical methodology, by
213 operators masked to the clinical diagnosis.²¹

214 The 3D left ventricular morphology was studied by the construction of a statistical shape
215 model from the segmentations of the short axis stack at the end diastolic frame as reported

216 in previous studies.²²⁻²⁴ Briefly, 3D meshes were built using a computational anatomy tool
217 kit,²⁵ anatomical modes of variation were found by Principal Component Analysis, and the
218 impact of pre-eclampsia was assessed by an optimised linear discriminant analysis of the
219 first 12 modes.

220 Flow data was processed using CVI42 Flow version 5.10.3. The magnitude image with the
221 sharpest contrast was used to determine vessel contours. Contours were then propagated
222 to phase contrast images (with manual correction as required) in all temporal phases.

223 All parameters were first assessed against gestational age, and then as cases against
224 controls. Matching was undertaken to nearest gestational age, with further analysis using
225 the Mann-Whitney U Test.

226 *Statistical Analysis*

227 Statistical analysis was performed with R version 3.6.0 (R Foundation for Statistical
228 Computing) and RStudio Server version 1.043, unless otherwise stated. Variables are
229 expressed as percentages if categorical, mean \pm SD if continuous and normal, and median
230 (interquartile range) if continuous and non-normal. Baseline anthropometric data were
231 compared by using Kruskal-Wallis tests and, if differences were identified, a Wilcoxon test
232 was used for pairwise comparisons with Benjamini-Hochberg adjustment for multiple
233 testing. Imaging parameters in 2 or more groups were compared by using analysis of
234 covariance, adjusted for relevant clinical covariates. When differences were significant, a
235 Tukey post hoc test was applied for pairwise multiple comparisons.

236

237 **Results**

238 *Study participants*

239 Seventy-eight scans were obtained from 65 pregnant women (with nine women having two scans,
240 and two having three scans). An additional 38 scans were obtained from healthy non-pregnant
241 controls. Cardiac assessment was not completed in two pregnant participants: one owing to
242 claustrophobia, and one to worsening hypertension. For a further 16 women, no cardiac
243 data were obtained. Nine women developed pregnancy complications after being scanned
244 as a control and so were moved to the complicated pregnancy cohort and excluded.
245 Thirteen women with pre-eclampsia were recruited, one of whom had three MRIs. Of the
246 13, six had pre-eclampsia superimposed on chronic hypertension. Table 2 summarises the
247 demographics of all cohorts. Supplementary Table 1 details relevant obstetric history and
248 outcomes of the pre-eclamptic cohort.

249 *Placenta*

250 In the cross-sectional control group, there was a decrease in mean T2* values across
251 gestation ($p < 0.01$). This was also seen as a trend (not reaching significance) in the chronic
252 hypertensive group. The pre-eclamptic cohort had significantly lower T2* values throughout
253 gestation, and a gradual decline was not seen. Both skewness and kurtosis increased
254 throughout gestation in the control group, with the chronic hypertensive group overlying
255 this, although not reaching significance. The pre-eclamptic group had higher skewness and
256 kurtosis than both other groups, and placental volume was reduced ($p = 0.02$) (Figure 3).
257 Three women with pre-eclampsia had placental T2* values similar to controls; of note these
258 were the only three women without any vascular abnormalities on placental histopathology
259 (Table 3, Supplementary Table S1).

260 Visual inspection of control versus pre-eclamptic placentas revealed a more variable lobule
261 size and less consistent signal intensity in women with pre-eclampsia. There was also an
262 increase in low signal areas as compared to controls.

263 *Fetal brain*

264 Fetal brain T2* values were demonstrated to decline with advancing gestation among
265 controls. This relationship was preserved in the chronic hypertensive group. Among women
266 with pre-eclampsia, the fetal brain T2* values were significantly reduced through all
267 gestations ($p < 0.01$) and did not have a linear decline with gestation (Figure 4). There were
268 three cases in which brain T2* was in line with controls; in all these cases fetal Doppler
269 studies were normal (Table 3, Supplementary Table S1). One case demonstrated an
270 abnormal T2* values but with preserved fetal Doppler studies (Table 3, Supplementary
271 Table S1). Brain volume was reduced in the presence of pre-eclampsia ($p = 0.03$) (Figure 4).
272 Z scores were generated for mean placental T2* values and mean fetal brain T2* values in
273 order to allow for direct comparison: there was a direct correlation between normal and
274 low scores in both domains (Figure 5).

275 Major differences in the placental and fetal findings of the control and pre-eclampsia groups
276 are summarised in Supplementary Figure 1.

277 *Cardiac MR*

278 Systolic ($p < 0.001$) and diastolic ($p = 0.03$) blood pressure were lower in the pregnant controls
279 (107 / 66 mmHg) than in pre-eclamptic participants (121 / 77 mmHg). There were no other
280 baseline anthropometric differences between groups.

281 After adjusting for body surface area (BSA), non-pregnant controls had lower heart rate (68
282 bpm vs 74.8 bpm; $p = 0.02$), cardiac output (5.5 L / min vs 6.2 L / min; $p = 0.02$), LV mass
283 (77.4 g vs 87 g; $p = 0.01$) and concentricity (LV mass / LV end-diastolic volume; 0.57 g / ml vs
284 0.64 g / L; $p = 0.01$) than pregnant participants. The LV mass of the pre-eclamptic group
285 (98.05 ± 24.5 g) was higher than both the pregnant controls (83.3 ± 12.08 g; $p = 0.04$) and
286 the non-pregnant group (77.4 ± 13.8 g; $p=0.04$). The study of the 3D anatomy revealed a
287 specific thickening pattern (existence of regional increase in wall thickness wall locations of
288 mid antero-lateral and postero-septal) together with changes in eccentricity (the ventricular
289 cross-section displayed a dilation in the axis oriented in the direction of the outflow tract)
290 and the onset of a bulge below the outflow track, see Figure 3. A detailed inspection of the
291 modes of anatomical variation further reveals that the thickening pattern associated to pre-
292 eclampsia was linked to a localised basal concentric remodelling and not to the
293 complementary basal eccentric remodelling (see modes 11 and 13 in Supplementary Figure
294 S2).

295 **Discussion**

296 *Summary of main findings*

297 We have demonstrated a comprehensive anatomical and functional MRI protocol for
298 cardiac and fetal-placental imaging that is safe in pregnancy and acceptable to women, with
299 97% of scans completed. As far as we are aware, this is the largest set of functional placental
300 MRI data in pre-eclamptic pregnancies, and confirms previous findings suggestive of altered
301 oxygenation and microstructure. We have demonstrated altered T2* in the fetal brain, in
302 proportion to that seen in the placenta. Finally, we have characterised the remodelling
303 pattern of the maternal left ventricle associated with the presence of pre-eclampsia.

304 Conventional cardiac MRI analysis demonstrated higher LVM in pre-eclampsia than in
305 uncomplicated pregnancies, while 3D statistical modelling revealed specific characteristics
306 of eccentricity and outflow track remodelling beyond the thickening of the walls.

307 *Strengths and limitations*

308 This is the largest study to date investigating maternal, fetal and placental implications of
309 pre-eclampsia *in vivo*. We utilise an optimised protocol²⁶ and includes novel findings related
310 to the T2* values. To our knowledge this is the first published study making a holistic
311 assessment of the fetal, placental and maternal implications of pre-eclampsia. The MRI
312 sequence described here is safe in pregnancy and acceptable to women, and gives insight
313 into pre-eclamptic pregnancies that cannot be obtained by other means during pregnancy.
314 The use of consistent maternal positioning and scanning protocols means that the data are
315 robust and comparable between subjects.

316 Functional placental data build on that previously presented to demonstrate abnormalities
317 in microstructure and oxygenation in the pre-eclamptic placenta.^{17,18} The inclusion of a non-
318 pregnant cardiac control group delineates changes expected in pregnancy from those that
319 are pathological. Motion correction and reconstruction of fetal images has allowed for the
320 first analysis of T2* brain maps in fetuses affected by pre-eclampsia. The inclusion of a
321 chronic hypertensive group demonstrates where phenotypes are driven by pre-eclampsia,
322 rather than the gestational effects of hypertension alone.

323 There are several limitations to this study: firstly, recruitment to the pre-eclampsia group
324 was challenging, largely due to the often short intervals from diagnosis to delivery and so
325 the study is relatively small, perhaps obscuring other significant differences between cases
326 and controls. Secondly, the lack of long-term follow up limits understanding of how much

327 the observed maternal cardiac and fetal brain changes directly impact chronic health
328 outcomes. Thirdly, the small sample size makes it difficult to comment on confounders
329 within the pre-eclampsia group, in particular the presence of diabetes, and early versus late
330 onset disease.

331 *Comparison to other work*

332 The placental phenotype in control pregnancies is in line with previous work: the reduction
333 in T2* across gestation in normal pregnancies has been demonstrated using both our
334 imaging protocols²⁶ and those that of others.^{27,28} As previously demonstrated, there is
335 overlap between chronic hypertensive pregnancies and normal pregnancies in terms of
336 mean T2*, skewedness and kurtosis.¹⁶ Pregnancies affected by pre-eclampsia are typically
337 outliers in all domains. This is to be expected given the higher rate of hypoxic vascular
338 anomalies seen in the pre-eclamptic placentae compared to that affected by chronic
339 hypertension alone.²⁹

340 In all cases where the placental T2* in pre-eclamptic pregnancies lay within the normal
341 range, there was normal placental histopathology and delivery at later gestations,
342 suggesting a less severe clinical phenotype. Pre-existing work on placental perfusion MRI in
343 women with early and late pre-eclampsia, where women with later onset disease has
344 demonstrated preserved placental perfusion.³⁰ The decreased placental perfusion seen in
345 the early pre-eclampsia group, as well as histopathological evidence for greater maternal
346 malperfusion in early onset pre-eclampsia as compared to late,³¹ provide basis for the
347 variation seen in our cohort. Our findings go further to support the ability of functional
348 placental MRI to differentiate between disease severities.

349 Novel to this study is the association between placental T2* and fetal brain T2*. The
350 negative correlation between decreasing brain T2* and increasing gestation in the normal
351 pregnancy is already established, and thought to be secondary to a number of structural
352 changes including decreasing water density and increasing myelination.³² Preservation of
353 brain volume with a decrease in T2* in the pre-eclampsia group may reflect a reduction in
354 oxygenation, with or without reduction in angiogenesis. This seems particularly likely given
355 that this does not seem to occur in the absence of reduced placental T2*, and that in all but
356 one case there is corresponding Doppler evidence of cerebral redistribution. Long-term
357 neurodevelopmental and behavioural outcomes of children born to mothers with pre-
358 eclampsia are recognised, and a small study has shown differences in neuroanatomy
359 persisting at 7-10yrs;³³ although this is difficult to disentangle from the effects of
360 prematurity, our findings may suggest an antenatal antecedent.

361 Looking into the mother's health, novel to this study is the 3D thickening pattern of the left
362 ventricle that is found discriminant of the presence of pre-eclampsia. The extra workload in
363 pre-eclampsia is indeed increasing the cardiac mass and mass to volume ratio, as previously
364 reported in much larger echocardiography studies.⁵ This demonstrates the higher power of
365 cardiac MRI to identify differences between small groups, and its role in cardiovascular
366 research in pregnancy. Our preliminary data further reveal an intriguing pattern of
367 thickening, eccentricity and bulging as illustrated in Figure 6. The fact that the other groups
368 of non-pregnant controls and chronic hypertension did not show differences with control
369 pregnancy along this axis suggests that this is an acute maladaptive remodelling process
370 specific to pre-eclampsia. In relationship with this finding, the chronic remodelling of the left
371 ventricle 5 to 10 years after a hypertensive pregnancy manifest as a global concentric (and
372 not eccentric) thickening of the left ventricle.³⁴ Intriguingly in the response of pre-eclampsia

373 during pregnancy it is only the base of the heart where this concentric (and not eccentric)
374 thickening pattern is seen (see Supplementary Figure S1). This collection of observations
375 leads us to hypothesize that it is the base of the heart the region that is first recruited and
376 most intensively working in response to pre-eclampsia, and that the rapid onset of
377 hypertension causes a level of uneven thickening pattern and septal bulging.

378 *Implications*

379 While clinical fetal MRI is largely confined to assessment of structural anomalies, there is
380 evidence here of a potential role for other high risk obstetric conditions. We have
381 demonstrated feasibility of a comprehensive fetal, placental and maternal cardiac MRI in
382 terms of safety, data acquisition and acceptability to women.

383 Future work into determining risk of developing, likely clinical severity and implications of
384 pre-eclampsia should combine MRI, obstetric ultrasound and biomarkers, as it is likely that a
385 combination of investigations could yield greatest information.

386 While we have demonstrated a correlation of findings associated with pre-eclampsia,
387 further work should be done in defining this phenotype. As well as increasing the cohort
388 size, attention should be paid to early and late onset disease, as these are likely to be
389 mechanistically different and have different clinical end point.³⁵ While fetal growth
390 restriction has previously been associated with reduced placental T2*,^{19,36} we have been
391 unable to delineate the implications of pre-eclampsia on this finding. Creation of a cohort
392 where the interplay between these three findings could be investigated would be of value.
393 MRI could have implications for earlier diagnosis of pre-eclampsia; high-risk women (for
394 example those with early onset growth restriction) who are not yet diagnosed with pre-
395 eclampsia should be included in future work, as this could have significant implications for

396 their management. Moreover, the 3D specific remodelling pattern linked to pre-eclampsia
397 could have implications for prognosis and risk models for future cardiovascular events. Any
398 future work on cardiac imaging should include longitudinal and postnatal data in order to
399 better delineate the mechanisms of continued cardiac risk, and for stratification of risk in
400 individuals.

401 In terms of perinatal outcomes, we have demonstrated a relationship between pre-
402 eclampsia and reduced fetal brain T2*, and also between reduced fetal brain T2* and fetal
403 cerebral Doppler redistribution. While there is some evidence of abnormal neurocognitive
404 outcomes in children who have been affected by redistribution (Beukers et al, 2017), further
405 neurocognitive follow up of children with paired MRI and ultrasound data could improve
406 understanding of the longer-term clinical implications of pre-eclampsia on the child.

407 In terms of techniques used, while the relationship between T2* and deoxyhaemoglobin is
408 well established, it is subject to influence from other factors. Therefore, additional
409 functional imaging, such as diffusion techniques, linked with recent advanced analysis
410 techniques³⁷ may lead to greater insight of the mechanisms of pre-eclampsia.

411 **Conclusions**

412 MRI of pregnancies affected by pre-eclampsia reveals a reduction in mean placental and
413 fetal brain T2*, with preservation of the volume of both organs. There is also an increase in
414 maternal cardiac work and specific thickening patterns of the left ventricle. This all
415 demonstrates that MRI is clinically valuable in risk stratification, investigation, and
416 management planning of women at high risk of pre-eclampsia, or who have been diagnosed
417 with the condition.

418 **Acknowledgments**

419 We are grateful to the women who participated in this study.

420 **Disclosures**

421 The authors declare no conflicts of interest.

422 **Funding**

423 This work was supported by core funding from the Wellcome/EPSRC Centre for Medical
424 Engineering [WT203148/Z/16/Z], by the NIH Human Placenta Project grant 1U01HD087202-
425 01 (Placenta Imaging Project (PIP)), by the Wellcome Trust, Sir Henry Wellcome Fellowship
426 to JH [201374/Z/16/Z] and Senior Research Fellowship to PL [209450/Z/17/Z]; National
427 Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; Medical
428 Research Council (MC_UP_1605/13); British Heart Foundation (RG/19/6/34387,
429 RE/18/4/34215); Academy of Medical Sciences (SGL015/1006) and Fetal Medicine
430 Foundation (495237). For the purpose of open access, the authors have applied a creative
431 commons attribution (CC BY) licence to any author accepted manuscript version arising.

432 **Table 1: Scanning parameters**

Placental and Fetal MRI	
Anatomical	T2 weighted Turbo Spin Echo TR 30s; TE 180ms; Matrix size 384x384x150; Resolution 1.25x1.25x2.5mm
T2* static	Multi-Echo Gradient Echo TR 23s; TE 12.599ms/65.34ms/118.08ms/170.821ms/223.562ms; Dynamics – 2; Matrix size 224x224x850; Resolution 2.5x2.5x2.5mm
Diffusion	Pulsed Gradient Echo Spin Echo, Echo Planar Imaging TR 6.6s; TE 78ms; Matrix 512x512x56; Resolution 2x2x4mm; b 375 (6 directions); b 750 (6 directions)
T2* dynamic	Multi-Echo Gradient Echo TR 6.4s; TE 7.84ms/60.574ms/113.308ms/116.041ms; Dynamics – 30; Matrix size 256x256x360; Resolution 2.5x2.5x2.5mm
Cardiac MRI	
Cine bSSFP	bSSFP 30 phases; FA 60; TR 4ms; TE 2ms; Resolution 1.7.1.7.8mm; ~11 second breath-hold
Short axis stack	bSSFP TR 4.1s; TE 2ms; 14 slices; Sense 2; Resolution 2x2x10mm
Phase contrast (breath-hold option)	30 phases; Sense 2; Resolution 2.5x2.5x8mm; 14 second breath-hold
Phase contrast (free breathing option)	30 phases; Sense 2; Resolution 2.5x2.5x5mm; NSA 4

433 *TR: repetition time; TE echo time; bSSFP balanced Steady State Free Precession*

434 **Table 2: Demographics of participants**

Cohort (number of scans)	Pregnant controls (n=32)	Non-pregnant controls (n=38)	Pre-eclampsia (n=15)	Chronic hypertension (n=22)	Complicated pregnancy (n=9)
Age (years), median (IQR)	34.4 (31.8-37.3)	32.0 (27.0-39.0)	33.5 (30.8-37.8)	36.8 (33.8-41.5)	33.1 (31.9-35.3)
BMI (kg/m²), median (IQR)	24.7 (22.9-27.2)	25.3 (21.2-25.4)	28.1 (24.1-33.2)	31.9 (27.4-33.8)	23.1 (21.9-24.4)
Gestational age at the time of scan (weeks), median (IQR)	28.1 (23-5-32.1)		32.7 (30.0-34.1)	27.8 (25.0-32.0)	27.3 (24.4-33.3)
Gestational age at birth, mean (SD)	39.6 (1.07)		33.4 (2.77)	37.8 (0.7)	36.3 (2.87)
Birth weight (grams), mean (SD)	3394 (402)		1781 (552)	2973 (636)	2370 (978)
Birth weight (grams), range	2710-4175		695-3070	1560-4840	1010-3220
Previous pre-eclampsia (%)	0	0	3 (25)	2 (8)	0

435 *BMI: body mass index; IQR: interquartile range*

436 **Table 3: Relationship between fetal brain and placental T2* and clinical parameters**


437

Participant ID	Placental T2*	Placental histopathology	Fetal brain T2*	Fetal Dopplers	Fetal growth restriction
1	Low	Abnormal	Low	Redistribution	Yes
2	Low	Other vascular abnormality	Low	Normal	Yes
3	Low	Abnormal	Low	Redistribution	Yes
4	Low	Abnormal	Low	Redistribution	No
5	Normal	Normal	Normal	Normal	No
6	Low	Abnormal	Low	Redistribution	Yes
7	Low	Abnormal	Low	Redistribution	Yes
8	Normal	No pre-eclampsia related changes	Normal	Normal	Yes
9	Low	Not available	Low	Redistribution	No
10	Low	Abnormal	Low	Redistribution	Yes
11	Low	Abnormal	Low	Redistribution	Yes
12	Low	Abnormal	Low	Redistribution	Yes
13	Normal	Normal	Normal	Normal	No

438


439

440 **Figure 1: Schematic of study protocol**




441
 442 *US: ultrasound; UtAD: uterine artery Doppler; AFI: amniotic fluid volume; UmbAD: umbilical*
 443 *artery Doppler; MCA: middle cerebral artery Doppler; DV: ductus venosus Doppler; BP blood*
 444 *pressure; CW cardiac work; CI: cardiac index; DW-SS EPI: diffusion weighted single shot echo*
 445 *planar imaging; 4C: 4 chamber; 2C 2 chamber; 3C 3 chamber; SA: short axis; aAo ascending*
 446 *aorta; dAo descending aorta; SVC superior vena cava.*

447 **Figure 2: Summary of images acquired on protocol**



448

449 **Figure 3: Placental anatomical and T2* by group**




450

451 *Figure 1: A) mean placental T2* by gestation; B) placental mass by gestation; C) skewness*

452 *and D) kurtosis by gestation. Black dot = healthy pregnancy; blue = chronic hypertension;*

453 *orange = pre-eclampsia.*

454 **Figure 4: Fetal brain anatomical and T2* by group**




455

456 *Figure 2: A) Fetal brain mean T2* by gestation; B) fetal brain volume by gestation. Black dot*

457 *= healthy pregnancy; blue = chronic hypertension; orange = pre-eclampsia.*


458 **Figure 5: Comparison of fetal brain mean T2* z-score and placental mean T2* z-score**



459

460 *Black dot = healthy pregnancy; blue = chronic hypertension; orange = pre-eclampsia.*

461 **Figure 6: Left ventricular remodelling associated with pre-eclampsia.**



462 *Figure 3: Left ventricular remodelling associated with pre-eclampsia (PE), illustrating*
463 *thickened walls and eccentricity & bulging located at the outflow track. **Top panel:** extremes*
464 *of the anatomical mode that best discriminate pregnant controls to pregnant pre-eclamptic*
465 *subjects - The 3D and bullseye views are colour-coded by thickness (in mm) and have black*
466 *and white spheres at the sides of the outflow track for easy mapping between both views –*
467 *A: Anterior; P: Posterior; L: Lateral; S: Septal. **Bottom panel:** box-plot of distributions of*
468 *pregnant controls (black), pre-eclampsia (blue), chronic hypertension (orange) and non-*
469 *pregnant controls (green), together with metrics of the discriminant performance of the*
470 *linear discriminant analysis between pregnant controls and pre-eclampsia (AUC: Area Under*
471 *the Curve; RS: Resubstitution; L1: Leave-1 out cross-validation).*

472

473 **Supplementary material**

474 **Supplementary Table S1: Medical history and obstetric outcomes of the pre-eclamptic cohort**

475


Ethnicity (n)	
White	2
Black	5
South Asian	4
Other	2
Parity (n)	
Nulliparous	9
Parous	4
Gestational age at PET diagnosis (weeks) (range)	27.0 (20.7 – 35.0)
Pre-eclampsia superimposed on chronic hypertension (n)	6
PIGF (pg/ml) (n)	
≥12	2
<12	2
Proteinuria (n)	13
Acute kidney injury (n)*	5
Hepatic dysfunction (n)*	8
Haemolysis (n)*	1
Neurological involvement (n)*	0
Thrombocytopenia (n)*	2
Fetal growth restriction (n)	10
Gestational age at MRI (weeks) (range)	32.0 (26.3 – 35.3)
Antenatal aspirin use (n)	7
Antihypertensives at time of MRI (n)	
Single agent	8
Two agents	4
Three agents	1
Maximum antihypertensives (n)	
Single agent	5
Two agents	4
Three agents	3
Four agents	1
Evidence of redistribution on ultrasound at time of MRI (n)	
Yes	9
No	4
Mode of delivery (n)	
Caesarean section in labour	2
Caesarean section prior to labour	10
Spontaneous vaginal	1
Indication for delivery (n)	
Maternal	4
Fetal	9
Neonatal complications (n)	

NICU admission	12
Respiratory support	4
Necrotising enterocolitis	2
Hypoglycaemia	5
Jaundice	6
Placental histopathology (n)	
Abnormalities consistent with pre-eclampsia	8
Other abnormalities	2
Normal	2
Not available	1

476 PIGF: placental growth factor.

477 *Diagnosed at any stage in pregnancy or postnatal period

478 **Supplementary Figure S1: Summary of major findings in the control and pre-eclamptic cohorts**




479 *Placental mean T2* p<0.001; placental volume p=0.02; placental T2* skewness p=0.03; placental T2**
 480 *kurtosis p=0.01.*

481 *Fetal brain mean T2* p<0.001; fetal brain volume p=0.03.*

482 *Cardiac output p=0.22; cardiac work p=0.905; mean systolic blood pressure p<0.001; mean diastolic*
 483 *blood pressure p=0.01; mean heart rate p=0.159*

484 *BP: blood pressure*

485 **Supplementary Figure S2: Anatomical models of variation that most correlate with**
486 **thickness**



487
488
489 *Sup. Fig. 1: The two anatomical modes of variation that most correlated with thickness*
490 *($R^2=22.89\%$ and 26.58% respectively for mode 11 and 13), with mode 11 showing a*
491 *concentric basal thickening (narrower cavity at the base) and with mode 13 showing a*
492 *complementary eccentric basal thickening (wider cavity at the base). Box-plots of the*
493 *subjects (pregnant control: black; pre-eclampsia: blue; non-pregnant control: green; chronic*
494 *hypertension: orange) show an almost significant difference in mode 11 between pregnant*
495 *control and pre-eclampsia ($p=0.07$) but the complete overlap in mode 13 ($p=0.77$).*

496 References

497

- 498 1. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. *Lancet*. 2021;398:341-354. doi:
499 10.1016/S0140-6736(20)32335-7
- 500 2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet*.
501 2010;376:631-644. doi: 10.1016/S0140-6736(10)60279-6
- 502 3. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M,
503 Alkema L. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health*.
504 2014;2:e323-333. doi: 10.1016/S2214-109X(14)70227-X
- 505 4. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different
506 maternal hemodynamic states in the latent phase of the disease. *Hypertension*.
507 2008;52:873-880. doi: 10.1161/HYPERTENSIONAHA.108.117358
- 508 5. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic
509 Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review. *Circ*
510 *Cardiovasc Imaging*. 2016;9. doi: 10.1161/CIRCIMAGING.116.004888
- 511 6. Melchiorre K, Sutherland G, Sharma R, Nanni M, Thilaganathan B. Mid-gestational maternal
512 cardiovascular profile in preterm and term pre-eclampsia: a prospective study. *BJOG*.
513 2013;120:496-504. doi: 10.1111/1471-0528.12068
- 514 7. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular
515 disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335:974.
516 doi: 10.1136/bmj.39335.385301.BE
- 517 8. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, Chappell L.
518 Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked
519 Electronic Health Records: A CALIBER Study. *Circulation*. 2019;140:1050-1060. doi:
520 10.1161/CIRCULATIONAHA.118.038080
- 521 9. Thilaganathan B. Maternal Cardiac Dysfunction Precedes Development of Preeclampsia.
522 *Hypertension*. 2020;76:321-322. doi: 10.1161/HYPERTENSIONAHA.120.15281
- 523 10. Garcia-Gonzalez C, Georgiopoulos G, Azim SA, Macaya F, Kametas N, Nihoyannopoulos P,
524 Nicolaidis KH, Charakida M. Maternal Cardiac Assessment at 35 to 37 Weeks Improves
525 Prediction of Development of Preeclampsia. *Hypertension*. 2020;76:514-522. doi:
526 10.1161/HYPERTENSIONAHA.120.14643
- 527 11. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ. Comparison of
528 interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional
529 echocardiography in normal subjects and in patients with heart failure or left ventricular
530 hypertrophy. *Am J Cardiol*. 2002;90:29-34. doi: 10.1016/s0002-9149(02)02381-0
- 531 12. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for
532 studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. *J*
533 *Cardiovasc Magn Reson*. 2000;2:271-278. doi: 10.3109/10976640009148691
- 534 13. Colford K, Price AN, Sigurdardottir J, Fotaki A, Steinweg J, Story L, Ho A, Chappell LC, Hajnal
535 JV, Rutherford M, et al. Cardiac and placental imaging (CARP) in pregnancy to assess
536 aetiology of preeclampsia. *Placenta*. 2022;122:46-55. doi: 10.1016/j.placenta.2022.03.012
- 537 14. Hakim J, Senterman MK, Hakim AM. Preeclampsia is a biomarker for vascular disease in both
538 mother and child: the need for a medical alert system. *Int J Pediatr*. 2013;2013:953150. doi:
539 10.1155/2013/953150
- 540 15. Falco ML, Sivanathan J, Laoreti A, Thilaganathan B, Khalil A. Placental histopathology
541 associated with pre-eclampsia: systematic review and meta-analysis. *Ultrasound Obstet*
542 *Gynecol*. 2017;50:295-301. doi: 10.1002/uog.17494
- 543 16. Ho A, Hutter J, Slator P, Jackson L, Seed PT, McCabe L, Al-Adnani M, Marnerides A, George S,
544 Story L, et al. Placental magnetic resonance imaging in chronic hypertension: A case-control
545 study. *Placenta*. 2021;104:138-145. doi: 10.1016/j.placenta.2020.12.006

- 546 17. Ho AEP, Hutter J, Jackson LH, Seed PT, McCabe L, Al-Adnani M, Marnerides A, George S,
547 Story L, Hajnal JV, et al. T2* Placental Magnetic Resonance Imaging in Preterm Preeclampsia:
548 An Observational Cohort Study. *Hypertension*. 2020;75:1523-1531. doi:
549 10.1161/HYPERTENSIONAHA.120.14701
- 550 18. Slator PJ, Hutter J, Palombo M, Jackson LH, Ho A, Panagiotaki E, Chappell LC, Rutherford MA,
551 Hajnal JV, Alexander DC. Combined diffusion-relaxometry MRI to identify dysfunction in the
552 human placenta. *Magn Reson Med*. 2019;82:95-106. doi: 10.1002/mrm.27733
- 553 19. Sinding M, Peters DA, Frøkjær JB, Christiansen OB, Petersen A, Ulbjerg N, Sørensen A.
554 Placental magnetic resonance imaging T2* measurements in normal pregnancies and in
555 those complicated by fetal growth restriction. *Ultrasound Obstet Gynecol*. 2016;47:748-754.
556 doi: 10.1002/uog.14917
- 557 20. de Marvao A, Dawes TJ, Shi W, Durighel G, Rueckert D, Cook SA, O'Regan DP. Precursors of
558 Hypertensive Heart Phenotype Develop in Healthy Adults: A High-Resolution 3D MRI Study.
559 *JACC Cardiovasc Imaging*. 2015;8:1260-1269. doi: 10.1016/j.jcmg.2015.08.007
- 560 21. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, Francis JM, Khanji MY,
561 Lukaschuk E, Lee AM, et al. Reference ranges for cardiac structure and function using
562 cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population
563 cohort. *J Cardiovasc Magn Reson*. 2017;19:18. doi: 10.1186/s12968-017-0327-9
- 564 22. Marciniak M, van Deutekom AW, Toemen L, Lewandowski AJ, Gaillard R, Young AA, Jaddoe
565 VWV, Lamata P. A three-dimensional atlas of child's cardiac anatomy and the unique
566 morphological alterations associated with obesity. *Eur Heart J Cardiovasc Imaging*.
567 2022;23:1645-1653. doi: 10.1093/ehjci/jeab271
- 568 23. Hermida U, Stojanovski D, Raman B, Ariga R, Young AA, Carapella V, Carr-White G, Lukaschuk
569 E, Piechnik SK, Kramer CM, et al. Left ventricular anatomy in obstructive hypertrophic
570 cardiomyopathy: beyond basal septal hypertrophy. *Eur Heart J Cardiovasc Imaging*. 2022.
571 doi: 10.1093/ehjci/jeac233
- 572 24. Balaban G, Halliday BP, Hammersley D, Rinaldi CA, Prasad SK, Bishop MJ, Lamata P. Left
573 ventricular shape predicts arrhythmic risk in fibrotic dilated cardiomyopathy. *Europace*.
574 2022;24:1137-1147. doi: 10.1093/europace/euab306
- 575 25. Lamata P, Niederer S, Nordsletten D, Barber DC, Roy I, Hose DR, Smith N. An accurate, fast
576 and robust method to generate patient-specific cubic Hermite meshes. *Med Image Anal*.
577 2011;15:801-813. doi: 10.1016/j.media.2011.06.010
- 578 26. Hutter J, Slator PJ, Jackson L, Gomes ADS, Ho A, Story L, O'Muircheartaigh J, Teixeira RPAG,
579 Chappell LC, Alexander DC, et al. Multi-modal functional MRI to explore placental function
580 over gestation. *Magn Reson Med*. 2019;81:1191-1204. doi: 10.1002/mrm.27447
- 581 27. Sinding M, Sørensen A, Hansen DN, Peters DA, Frøkjær JB, Petersen AC. T2* weighted
582 placental MRI in relation to placental histology and birth weight. *Placenta*. 2021;114:52-55.
583 doi: 10.1016/j.placenta.2021.07.304
- 584 28. Schabel MC, Roberts VHJ, Gibbins KJ, Rincon M, Gaffney JE, Streblow AD, Wright AM, Lo JO,
585 Park B, Kroenke CD, et al. Quantitative longitudinal T2* mapping for assessing placental
586 function and association with adverse pregnancy outcomes across gestation. *PLoS One*.
587 2022;17:e0270360. doi: 10.1371/journal.pone.0270360
- 588 29. Stanek J. Placental pathology varies in hypertensive conditions of pregnancy. *Virchows Arch*.
589 2018;472:415-423. doi: 10.1007/s00428-017-2239-3
- 590 30. Sohlberg S, Mulic-Lutvica A, Lindgren P, Ortiz-Nieto F, Wikström AK, Wikström J. Placental
591 perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance
592 imaging study. *Placenta*. 2014;35:202-206. doi: 10.1016/j.placenta.2014.01.008
- 593 31. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS.
594 Placental lesions associated with maternal underperfusion are more frequent in early-onset
595 than in late-onset preeclampsia. *J Perinat Med*. 2011;39:641-652. doi:
596 10.1515/jpm.2011.098

- 597 32. Vasylechko S, Malamateniou C, Nunes RG, Fox M, Allsop J, Rutherford M, Rueckert D, Hajnal
598 JV. T2* relaxometry of fetal brain at 1.5 Tesla using a motion tolerant method. *Magn Reson*
599 *Med.* 2015;73:1795-1802. doi: 10.1002/mrm.25299
- 600 33. Figueiró-Filho EA, Mak LE, Reynolds JN, Stroman PW, Smith GN, Forkert ND, Paolozza A,
601 Rätsep MT, Croy BA. Neurological function in children born to preeclamptic and
602 hypertensive mothers - A systematic review. *Pregnancy Hypertens.* 2017;10:1-6. doi:
603 10.1016/j.preghy.2017.07.144
- 604 34. Boardman H, Lamata P, Lazdam M, Verburg A, Siepmann T, Upton R, Bilderbeck A, Dore R,
605 Smedley C, Kenworthy Y, et al. Variations in Cardiovascular Structure, Function, and
606 Geometry in Midlife Associated With a History of Hypertensive Pregnancy. *Hypertension.*
607 2020;75:1542-1550. doi: 10.1161/HYPERTENSIONAHA.119.14530
- 608 35. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with
609 early- versus late-onset disease. *Am J Obstet Gynecol.* 2013;209:544.e541-544.e512. doi:
610 10.1016/j.ajog.2013.08.019
- 611 36. He J, Chen Z, Chen C, Liu P. Comparative study of placental T2* and intravoxel incoherent
612 motion in the prediction of fetal growth restriction. *Placenta.* 2021;111:47-53. doi:
613 10.1016/j.placenta.2021.06.005
- 614 37. Slator PJ, Hutter J, Marinescu RV, Palombo M, Jackson LH, Ho A, Chappell LC, Rutherford M,
615 Hajnal JV, Alexander DC. Data-Driven multi-Contrast spectral microstructure imaging with
616 InSpect: INtegrated SPECTral component estimation and mapping. *Med Image Anal.*
617 2021;71:102045. doi: 10.1016/j.media.2021.102045

618